

UCSF

UC San Francisco Previously Published Works

Title

Association of day-of-injury plasma glial fibrillary acidic protein concentration and six-month posttraumatic stress disorder in patients with mild traumatic brain injury

Permalink

<https://escholarship.org/uc/item/5h82619j>

Journal

Neuropsychopharmacology, 47(13)

ISSN

0893-133X

Authors

Kulbe, Jacqueline R

Jain, Sonia

Nelson, Lindsay D

et al.

Publication Date

2022-12-01

DOI

10.1038/s41386-022-01359-5

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

ARTICLE OPEN



Association of day-of-injury plasma glial fibrillary acidic protein concentration and six-month posttraumatic stress disorder in patients with mild traumatic brain injury

Jacqueline R. Kulbe¹, Sonia Jain², Lindsay D. Nelson³, Frederick K. Korley⁴, Pratik Mukherjee^{5,6}, Xiaoying Sun², David O. Okonkwo⁷, Joseph T. Giacino^{8,9}, Mary J. Vassar^{10,11}, Claudia S. Robertson¹², Michael A. McCrea³, Kevin K. W. Wang¹³, Nancy Temkin¹⁴, Christine L. Mac Donald¹⁴, Sabrina R. Taylor^{10,11}, Adam R. Ferguson¹⁰, Amy J. Markowitz¹⁰, Ramon Diaz-Arrastia¹⁵, Geoffrey T. Manley^{10,11}, Murray B. Stein^{1,16,17}✉ and TRACK-TBI Investigators*

© The Author(s) 2022, corrected publication 2022

Several proteins have proven useful as blood-based biomarkers to assist in evaluation and management of traumatic brain injury (TBI). The objective of this study was to determine whether two day-of-injury blood-based biomarkers are predictive of posttraumatic stress disorder (PTSD). We used data from 1143 individuals with mild TBI (mTBI; defined as admission Glasgow Coma Scale [GCS] score 13–15) enrolled in TRACK-TBI, a prospective longitudinal study of level 1 trauma center patients. Plasma glial fibrillary acidic protein (GFAP) and serum high sensitivity C-reactive protein (hsCRP) were measured from blood collected within 24 h of injury. Two hundred and twenty-seven (19.9% of) patients had probable PTSD (PCL-5 score ≥ 33) at 6 months post-injury. GFAP levels were positively associated (Spearman's $\rho = 0.35$, $p < 0.001$) with duration of posttraumatic amnesia (PTA). There was an inverse association between PTSD and (log)GFAP (adjusted OR = 0.85, 95% CI 0.77–0.95 per log unit increase) levels, but no significant association with (log)hsCRP (adjusted OR = 1.11, 95% CI 0.98–1.25 per log unit increase) levels. Elevated day-of-injury plasma GFAP, a biomarker of glial reactivity, is associated with reduced risk of PTSD after mTBI. This finding merits replication and additional studies to determine a possible neurocognitive basis for this relationship.

Neuropsychopharmacology (2022) 47:2300–2308; <https://doi.org/10.1038/s41386-022-01359-5>

INTRODUCTION

Many patients with mild TBI (mTBI; i.e., those with initial Glasgow Coma Scores [GCS] of 13–15) do not fully recover from their injury [1] and psychological health problems such as posttraumatic stress disorder (PTSD) frequently contribute to residual dysfunction and reduced quality of life [2, 3]. PTSD is seen in upwards of 20% of patients with mTBI and more commonly than in patients with non-head orthopedic injuries [4, 5].

The observation that PTSD is more common in association with head than non-head injuries has led to hypotheses that brain injury – likely involving damage to specific regions or disruption of connections to the hippocampus, frontal and cingulate cortex, insula or amygdala – explains, at least in part, this association [3, 5–7]. We have shown that smaller volume of several of these structures assessed 2 weeks post-injury, but still presumably reflecting the *pre-injury* state, are associated with greater

likelihood of PTSD 3 months post-injury [8]. To the best of our knowledge, there are no studies that prospectively and systematically relate the extent of parenchymal injury to PTSD in patients with TBI. The absence of such data reflects the difficulty in obtaining standardized imaging measures post-injury, a problem that might be addressed by the availability of blood-based biomarkers of brain injury [9, 10].

Over the past several years there have been meaningful advances in the development and validation of blood-based biomarkers of traumatic brain injury [10]. In a prospective cohort study of 584 adult trauma patients seen at level I trauma centers, glial fibrillary acidic protein (GFAP) – which is believed to be a specific marker of astrocyte activation [11] – performed consistently well in detecting mild-to-moderate TBI and presence or absence of CT abnormalities [12]. A study of US military cadets during combat training showed that plasma levels of GFAP

¹Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA. ²Biostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA. ³Departments of Neurosurgery and Neurology, Medical College of Wisconsin, Milwaukee, WI, USA. ⁴Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA. ⁵Department of Radiology & Biomedical Imaging, UCSF, San Francisco, CA, USA. ⁶Department of Bioengineering & Therapeutic Sciences, UCSF, San Francisco, CA, USA. ⁷Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. ⁸Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA. ⁹Spaulding Rehabilitation Hospital, Charlestown, MA, USA. ¹⁰Brain and Spinal Cord Injury Center, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, CA, USA. ¹¹Department of Neurological Surgery, UCSF, San Francisco, CA, USA. ¹²Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA. ¹³Department of Emergency Medicine, University of Florida, Gainesville, FL, USA. ¹⁴Department of Neurological Surgery, University of Washington, Seattle, WA, USA. ¹⁵Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. ¹⁶School of Public Health, University of California, San Diego, La Jolla, CA, USA. ¹⁷VA San Diego Healthcare System, San Diego, CA, USA. *A list of authors and their affiliations appears at the end of the paper.

✉email: mstein@health.ucsd.edu

Received: 18 April 2022 Revised: 16 May 2022 Accepted: 31 May 2022

Published online: 18 June 2022

differentiated those with and without acute concussions at the acute post-injury point (<6 h) and at the 24–48 h post-injury point [13]. GFAP levels are elevated in athletes with sports-related concussion, and those with loss of consciousness (LOC) or posttraumatic amnesia (PTA) have significantly higher levels than athletes with concussion but neither LOC or PTA [14]. It has also recently been shown that day-of-injury plasma GFAP levels may be useful in the detection of brain injury on MRI even among patients with normal head CT scans [15]. Diagnostic aids for TBI based on GFAP and another blood-based biomarker—ubiquitin C-terminal hydrolase-L1 (UCH-L1) – have recently obtained regulatory approval (Banyan Brain Trauma Indicator Test. Banyan Biomarkers; 2018; i-STAT TBI Plasma Cartridge. Abbott Point of Care Inc. Abbott Park, IL; 2020) [16].

Whereas the aforementioned studies suggest that GFAP appears to be a useful blood-based biomarker of both the presence and initial severity of TBI, limited work has investigated its value in predicting longer-term outcomes such as the psychological conditions that are prevalent in the mTBI population. Here, using prospective longitudinal data from the multicenter Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) study, we characterized the relationship between day-of-injury plasma GFAP, injury characteristics (in particular, PTA, considered to be a marker of injury severity), and 6-month probable PTSD. Our primary hypothesis was that increased GFAP levels would be associated with increased risk of PTSD post-injury. We chose to evaluate GFAP because its peak in plasma (approximately 20 h after injury with a slow decline thereafter through 72 h) is closest to the timing of the initial post-injury blood sample drawn in TRACK-TBI (within 24 h of injury) and is therefore likely to be a better indicator of the extent of parenchymal injury than other biomarker candidates such as UCH-L1, which rises rapidly and peaks at 8 h post-injury [12]. We further hypothesized that plasma GFAP within 24 h of injury would be associated with extent of posttraumatic amnesia, thereby reflecting another correlate of injury severity (though all within the initial GCS 13–15 range of mTBI).

Lastly, we compared and contrasted results with a blood-based biomarker of tissue injury and inflammation that is not brain-specific but has been shown to be predictive of 6-month disability after TBI [17], high sensitivity C-reactive protein (hsCRP). Noting that some studies have found an association between serum levels of hsCRP and PTSD symptoms [18], we also hypothesized that hsCRP levels would be associated with PTSD, but not as strongly as GFAP levels. In testing these hypotheses, we thought it important to take into consideration possibly confounding factors known to influence risk for PTSD in the context of mTBI (e.g., female sex, cause of injury, history of pre-injury mental disorder, and abnormalities on CT) [5, 19].

PARTICIPANTS AND METHODS

Overview

TRACK-TBI is an 18-center prospective observational study of subjects evaluated in level I trauma centers within 24 h of injury from 2/26/2014 through 8/08/2018 [1]. We analyzed data from 1625 subjects, age ≥ 17 years, with GCS ED arrival score between 13 and 15, who were enrolled between March 2014 and July 2018, and had day-of-injury plasma GFAP and serum hsCRP measurements. Of these, 1143 completed the 6-month assessment. Inclusion criteria comprised having one's treating physician order a head computed tomography (CT) scan due to suspicion of TBI; meeting the American Congress of Rehabilitation Medicine's (ACRM) definition of TBI; enrollment for the study blood draw within 24 h of injury; adequate visual acuity/hearing pre-injury; and fluency in English or Spanish. Exclusion criteria included: significant polytrauma that would interfere with follow-up; penetrating TBI; prisoners or patients in custody; pregnancy; patients under psychiatric care without consent; major debilitating mental (e.g., schizophrenia or bipolar disorder) or neurological disorders (eg, stroke, dementia) or any other disorder that would interfere with assessment and follow-up or provision of informed consent; current participant in an interventional trial.

Written informed consent was obtained from subjects or legally authorized representatives. The study was approved by the institutional review boards of enrolling sites.

Demographic and clinical data were obtained by experienced research assistants through medical record review and/or subject interviews. Head CT scans were sent to a central imaging repository and were read by a single board-certified neuroradiologist based on the Common Data Elements (CDE) in Radiologic Imaging of Traumatic Brain Injury [20].

Measures

Primary outcome. PTSD Checklist for DSM-5 (PCL-5): The PCL-5 is a widely used measure of posttraumatic stress disorder symptoms. The range of the scale is 0–80. Signal detection analyses against a clinical gold standard revealed that PCL-5 cut scores of 31 to 33 were optimally efficient for diagnosing PTSD [21]. Consistent with our prior work in this area, we used scores of ≥ 33 to indicate probable PTSD [5].

Glasgow Coma Scale (GCS). The GCS is a widely used estimate of brain injury severity that characterizes gross level of consciousness soon after injury (range 3–15; 13–15 is customarily considered “mild” TBI) [22].

Injury characteristics. The TRACK-TBI assessment obtained from the respondent and the medical record information about the characteristics of the injury included (a) cause of injury (e.g., motor vehicle collision; fall; other accidental injury; assault); (b) occurrence and duration of disturbance in consciousness or LOC; and (c) occurrence and duration of PTA.

Past medical history. The TRACK-TBI Interview requested information from the respondent (acquired at baseline, and in some cases collected from a relative or other suitable informant) about prior TBI(s) and prior history of mental disorder.

Blind sampling. Blood samples were obtained within 24 h of injury, processed, aliquoted, and stored in a -80°C freezer within 2 h of collection. Sample acquisition, processing, and storage were performed following the TBI-CDEs Biospecimens and Biomarkers Working Group Guidelines [23]. Coded samples were then shipped overnight and on dry ice to a central repository, and from the central repository to the laboratory for analysis. Sample analysis occurred in a single laboratory (Abbott Laboratories, Abbott Park, IL) by personnel blinded to sample information. Plasma samples used in this analysis underwent one freeze-thaw cycle.

Assays

Blinded sample analysis of hsCRP was carried out by a single laboratory (University College of Dublin) using the Abbott Architect c8000, MULTIGENT CRP Vario assay using the high-sensitivity method (CRP16). Anti-CRP antibodies adsorbed to latex particles agglutinate when an antigen-antibody reaction occurs with CRP, resulting in a change in absorbance proportional to the quantity of CRP in the sample. Serum samples were thawed in batches at room temperature and centrifuged at 1500 rfc for 10 min at 4°C before testing. Assays were performed in duplicate with a lower limit of quantification of 0.1 mg/L and a reportable range of 0.1–160.0 mg/L.

The first batch of GFAP concentrations ($n = 990$) was measured using the prototype point-of-care i-STAT[™] Alinity[™] System. The second batch of GFAP concentrations ($n = 635$) was measured on the prototype core lab Abbott ARCHITECT[®] platform for faster throughput. The i-STAT[™] Alinity[™] GFAP test uses the sandwich enzyme-linked immunosorbent assay (ELISA) method with electrochemical detection of the resulting enzyme signal. The GFAP assay's reportable range was from 0 to 50,000 pg/mL. The limit of detection (LoD) and limit of quantitation (LoQ) were <15 pg/mL and <25 pg/mL, respectively. Within-laboratory precision, measured by the coefficient of variation (CV), was 2.8 to 14.2%.

The prototype ARCHITECT[®] GFAP assay is a two-step sandwich assay that use a chemiluminescent microparticle immunoassay (CMIA) technology. The prototype GFAP assay calibration range was from 0 to 50,000 pg/mL. The LoD and LoQ were 2 pg/mL and 5 pg/mL, respectively, for a reportable range of 2–50,000 pg/mL. The within-laboratory CV was 2.0 to 5.6%. Samples with values greater than 50,000 pg/mL were retested with a 10-fold automated dilution protocol. All samples were tested neat, without dilution, and in duplicate. Samples reading greater than the calibration range were reported as greater than the reportable range and were not diluted. ARCHITECT[®] GFAP values were converted to iSTAT equivalents using a previously derived and validated (Spearman's correlation

Table 1. Demographic and clinical characteristics of the study cohort.

	Had PTSD outcome at 6m post-injury		Total	p-value
	No	Yes		
Age Median (IQR)	38 (26, 55)	38 (25, 55)	38 (26, 55)	0.396
Years of Education Median (IRQ)	12 (11, 14)	13 (12, 16)	13 (12, 16)	<0.001
Patient Type				
ED Discharge	114 (23.65%)	339 (29.66%)	453 (27.88%)	<0.001
Hospital admit no ICU	186 (38.59%)	488 (42.69%)	674 (41.48%)	
Hospital admit with ICU	182 (37.76%)	316 (27.65%)	498 (30.65%)	
Total	482 (100%)	1143 (100%)	1625 (100%)	
Gender				
Male	351 (72.82%)	740 (64.74%)	1091 (67.14%)	0.002
Female	131 (27.18%)	403 (35.26%)	534 (32.86%)	
Total	482 (100%)	1143 (100%)	1625 (100%)	
Race				
White	376 (80.17%)	865 (75.94%)	1241 (77.18%)	0.117
Black	72 (15.35%)	198 (17.38%)	270 (16.79%)	
Other	21 (4.48%)	76 (6.67%)	97 (6.03%)	
Total	469 (100%)	1139 (99.99%)	1608 (100%)	
Hispanic				
Non-Hispanic	343 (72.82%)	945 (83.04%)	1288 (80.05%)	<0.001
Hispanic	128 (27.18%)	193 (16.96%)	321 (19.95%)	
Total	471 (100%)	1138 (100%)	1609 (100%)	
Injury Cause				
Road traffic incident	260 (54.05%)	645 (56.63%)	905 (55.86%)	0.551
Incidental fall	141 (29.31%)	315 (27.66%)	456 (28.15%)	
Violence/assault	37 (7.69%)	70 (6.15%)	107 (6.6%)	
Other	43 (8.94%)	109 (9.57%)	152 (9.38%)	
Total	481 (99.99%)	1139 (100.01%)	1620 (100%)	
Prior TBI				
No	309 (71.36%)	763 (67.34%)	1072 (68.45%)	0.129
Yes	124 (28.64%)	370 (32.66%)	494 (31.55%)	
Total	433 (100%)	1133 (100%)	1566 (100%)	
Psychiatric History				
No	383 (79.63%)	868 (75.94%)	1251 (77.03%)	0.121
Yes	98 (20.37%)	275 (24.06%)	373 (22.97%)	
Total	481 (100%)	1143 (100%)	1624 (100%)	
GCS ED Arrival				
13	32 (6.64%)	49 (4.29%)	81 (4.98%)	0.114
14	83 (17.22%)	220 (19.25%)	303 (18.65%)	
15	367 (76.14%)	874 (76.47%)	1241 (76.37%)	
Total	482 (100%)	1143 (100.01%)	1625 (100%)	
LOC				
No	62 (12.89%)	142 (12.47%)	204 (12.59%)	0.964
Yes	396 (82.33%)	941 (82.62%)	1337 (82.53%)	
Unknown	23 (4.78%)	56 (4.92%)	79 (4.88%)	
Total	481 (100%)	1139 (100.01%)	1620 (100%)	
Posttraumatic Amnesia (PTA)				
No	93 (19.33%)	212 (18.61%)	305 (18.83%)	0.393
Yes	357 (74.22%)	831 (72.96%)	1188 (73.33%)	
Unknown	31 (6.44%)	96 (8.43%)	127 (7.84%)	
Total	481 (99.99%)	1139 (100%)	1620 (100%)	

Table 1. continued

	Had PTSD outcome at 6m post-injury		Total	p-value
	No	Yes		
CT Intracranial Injury				0.12
CT−	277 (60.61%)	725 (64.79%)	1002 (63.58%)	
CT+	180 (39.39%)	394 (35.21%)	574 (36.42%)	
Total	457 (100%)	1119 (100%)	1576 (100%)	
Sampling Time (hours)				0.351
0–8h	100 (20.75%)	274 (23.97%)	374 (23.02%)	
9–16h	148 (30.71%)	341 (29.83%)	489 (30.09%)	
17–24h	234 (48.55%)	528 (46.19%)	762 (46.89%)	
Total	482 (100.01%)	1143 (99.99%)	1625 (100%)	

coefficient = 0.985) equation: $iSTAT = -12.36 + 1.02 * ARCHITECT$ [24]. Technicians performing biomarker measurements were blinded to clinical outcome data.

Statistical analysis

Demographics and clinical characteristics were summarized for the study cohort. Group comparisons used the Wilcoxon Rank Sum test for the continuous variables and Fisher's exact test for categorical variables. Biomarker concentrations were not normally distributed and were summarized by reporting medians and their corresponding interquartile range. Log-transformed biomarker levels were used for modeling. Biomarker concentrations that were below the LoD were analyzed using the reported value and values above the assay's upper limit were assigned the upper limit. Receiver operating characteristic (ROC) analysis was performed to assess the discriminative ability of day-of-injury hsCRP or GFAP for predicting PTSD at 6 months postinjury for all mTBI cases. The area under the ROC curve (AUC) was calculated with its 95% confidence interval.

Multivariable logistic regression models assessed whether day-of-injury levels of hsCRP or GFAP were independent predictors of PTSD adjusting for known risk factors based on our prior models using demographics, injury characteristics and medical history [5]. The models also adjusted for sampling time (as 0–8, 9–16, or 17–24 h post-injury). Missing values in the baseline covariates were imputed using multiple imputation methods; [25] no outcome data were imputed [26]. As seen in Table 1, "PTA status" had the largest amount of missingness (8.7%) because unknown was treated as missing in the models; CT status had ~2% missing, and other baseline covariates had <1% missing. Pooled results from multiple imputed datasets were reported. Statistical significance was set as a p -value <0.05. Statistical analyses were conducted in R, version 4.1.2 (R Core Team, 2013).

RESULTS

A total of 1625 TRACK-TBI participants with day-of-injury GFAP and hsCRP measures and ED admission GCS 13–15 were available (see Supplementary Fig. 1: STROBE Diagram of study cohort). Of these, 1143 completed the PCL-5 assessment at 6-months post-injury (see Supplementary Fig. 2), and 227 (19.9%) had probable PTSD (PCL-5 \leq 33) at 6-months post-injury. Detailed demographic and clinical characteristics of the study population, shown as a comparison of participants for whom this outcome measure was or was not available, are shown in Table 1, with the latter group more likely to be Hispanic, male, less educated, and to have been admitted to the ICU. The median age of the 1,143 patients included in these analyses was 38 (IQR: 25–55) years. The sample was predominantly male (64.7%) and 56.6% were injured in road traffic accidents. The median time between injury and blood draw was 15.1 (IQR: 8.5–20.0) h.

Baseline factors associated with GFAP and hsCRP

There was a dose-dependent relationship (Spearman's $\rho = 0.353$, $p < 0.001$) between day-of-injury GFAP levels and duration of reported posttraumatic amnesia (PTA); those with higher GFAP levels had longer reported PTA (Fig. 1a). A relationship was also seen between day-of-injury hsCRP and PTA, albeit with hsCRP levels being elevated




Fig. 1 Relationship of Blood Biomarker Concentrations to Duration of Posttraumatic Amnesia. **a** (top): Day-of-injury plasma GFAP concentrations and duration of posttraumatic amnesia (PTA). **b** (bottom): Day-of-injury serum hsCRP concentrations and duration of posttraumatic amnesia (PTA).

only among participants with PTA extending beyond 24 h (who would not meet ACRM criteria for mTBI) (Fig. 1b). Multivariable models assessing the association between baseline factors and (log)GFAP and (log)hsCRP are shown in Table 2a and Table 2b, respectively.

GFAP and hsCRP values and PTSD Outcomes

Day-of-injury GFAP values were significantly ($p < 0.0001$) lower in participants with (median: 142.9 [IQR: 21.0–529.3] pg/ml) versus those without (median: 314.0 [IQR: 84.6–924.3] pg/ml) probable PTSD at the 6-month assessment (Fig. 2a). The AUC for GFAP levels

Table 2. Multivariable models.

	Coefficient (95% CI)	Wald's Chi-square	p-value
(a) Multivariable model assessing the association between baseline factors and day-of-injury (log)GFAP levels.			
Age	0.007 (0.002, 0.012)	8.61	0.003
Sex Female vs Male	-0.288 (-0.464, -0.113)	10.35	0.001
Race		3.07	0.215
Black vs White	-0.178 (-0.404, 0.049)		
Other vs White	0.103 (-0.232, 0.439)		
Hispanic Yes vs No	-0.092 (-0.308, 0.124)	0.7	0.404
Injury cause Violence vs Incident/other	-0.391 (-0.719, -0.064)	5.49	0.019
Psychiatric history Yes vs No	-0.216 (-0.408, -0.024)	4.85	0.028
Prior TBI Yes vs No	-0.283 (-0.458, -0.109)	10.1	0.001
CT + vs -	1.610 (1.431, 1.789)	309.7	<0.001
PTA Yes vs No	0.900 (0.704, 1.097)	80.5	<0.001
Sampling Time		32.45	<0.001
9-16h vs 0-8h	0.648 (0.424, 0.871)		
17-24h vs 0-8h	0.422 (0.214, 0.630)		
(b) Multivariable model assessing the association between baseline factor and day-of-injury (log)hsCRP levels.			
Age	0.009 (0.005, 0.013)	18.86	<0.001
Sex Female vs Male	-0.098 (-0.251, 0.055)	1.59	0.208
Race		4.01	0.134
Black vs White	0.081 (-0.116, 0.278)		
Other vs White	-0.252 (-0.544, 0.039)		
Hispanic Yes vs No	0.495 (0.307, 0.682)	26.64	<0.001
Injury cause Violence vs Incident/other	-0.233 (-0.518, 0.052)	2.57	0.109
Psychiatric history Yes vs No	-0.184 (-0.351, -0.016)	4.63	0.031
Prior TBI Yes vs No	-0.107 (-0.259, 0.045)	1.91	0.167
CT + vs -	0.321 (0.164, 0.477)	16.2	<0.001
PTA Yes vs No	0.183 (0.012, 0.354)	4.39	0.036
Sampling Time		629	<0.001
9-16h vs 0-8h	1.384 (1.190, 1.579)		
17-24h vs 0-8h	2.307 (2.125, 2.488)		

distinguishing between participants with and without probable PTSD at 6-months post-injury was 0.61 (95% CI: 0.57-0.66).

Day-of-injury hsCRP values did not significantly differ ($p = 0.53$) between participants with (median: 9.40 [IQR: 2.42-25.95] mg/L) and without (median: 6.93 [IQR: 2.21-25.96] mg/L) probable PTSD at the 6-month assessment (Fig. 2b). The AUC for hsCRP levels distinguishing between participants with and without probable PTSD at 6-months post-injury was no better than chance: 0.51 (95% CI: 0.47-0.56).

A multivariable logistic regression model including multiple known risk factors for PTSD (including age, sex, race, injury cause [violent vs. other], history of mental illness, CT scan results [positive vs. negative], history of prior TBI, and time of blood sampling) after TBI failed to show significant associations of (log)hsCRP with 6-month probable PTSD (adjusted OR = 1.11, 95% CI 0.98-1.25, $p = 0.11$), but continued to show significant associations of (log)GFAP with 6-month probable PTSD (adjusted OR = 0.85, 95% CI 0.77-0.95 per log unit increase; $p = 0.003$) (Table 3).

In a sensitivity analysis using the same predictors but excluding subjects with PTA > 24 h (who would not meet ACRM criteria for mTBI), we continued to see a significant association between higher (log)GFAP concentration and lower odds of 6-month probable PTSD (see Supplementary Table).

In a second sensitivity analysis using the same predictors in a multivariable linear regression with PCL-5 as a continuous outcome measure of PTSD symptoms, higher (log)GFAP was significantly associated with lower 6-month PCL-5 score (Table 4).

DISCUSSION

Traumatic brain injury represents a significant health crisis in the United States and worldwide. The majority of TBIs are classified as mild (GCS 13-15) [9]. Although a majority of individuals that sustain a mild TBI will go on to recover completely, up to 20% will go on to suffer from psychiatric illness such as PTSD, particularly in the first 6 months post-injury [3, 5, 6]. With finite healthcare resources available, the ability to predict clinical outcomes to allocate resources toward individuals at the greatest risk of developing chronic post-TBI symptoms and disability would lead to both cost-savings and improvement in individual quality of life. This is particularly true for sequelae such as PTSD, for which proven clinical interventions exist. In fact, implementing clinical intervention as soon as possible following a traumatic event leads to decreased likelihood of developing PTSD [27].




Fig. 2 Day-of-injury blood biomarker concentrations among those without and with probable PTSD at 6-month outcome. **a** (top): Day-of-injury plasma GFAP concentrations among those without (“no”) and with (“yes”) probable PTSD at 6-month outcome. **b** (bottom): Day-of-injury serum hsCRP concentrations among those without (“no”) and with (“yes”) probable PTSD at 6-month outcome post-injury.

Table 3. Multivariable logistic regression model for predicting probable PTSD 6 Months post-injury ($N = 1143$).

	OR (95% CI)	p-value
Age	0.995 (0.986, 1.006)	0.322
Sex Female vs Male	1.425 (1.019, 1.994)	0.039
Race Black vs non-Black	2.816 (1.935, 4.098)	<0.001
Injury cause Violence vs Incident/other	2.656 (1.489, 4.736)	<0.001
Psychiatric history Yes vs No	2.408 (1.702, 3.406)	<0.001
Prior TBI Yes vs No	1.586 (1.138, 2.211)	0.007
CT + vs –	0.837 (0.555, 1.262)	0.395
Sampling Time		
9–16h vs 0–8h	1.347 (0.826, 2.196)	0.232
17–24h vs 0–8h	1.800 (1.104, 2.934)	0.019
GFAP (in log scale)	0.851 (0.766, 0.946)	0.003
hsCRP (in log scale)	1.105 (0.977, 1.251)	0.113

AUC = 0.723, 95% CI: (0.682, 0.76); Nagelkerke’s pseudo-R-squared = 0.168; likelihood ratio test comparing this model to the model without biomarkers and sampling time showed p -value < 0.001.

Previous studies have indicated that there are certain demographic features such as sex, race, type of injury, and post-traumatic amnesia (PTA) that correlate with an increased risk of

Table 4. Multivariable linear regression model for predicting PCL-5 Score 6 Months post-injury.

	Coefficient (95% CI)	p-value
Age	−0.067 (−0.125, −0.01)	0.021
Sex Female vs Male	3.953 (1.868, 6.039)	<0.001
Race Black vs non-Black	8.636 (6.018, 11.253)	<0.001
Injury cause Violence vs Incident/other	9.525 (5.389, 13.661)	<0.001
Psychiatric history Yes vs No	7.163 (4.844, 9.482)	<0.001
Prior TBI Yes vs No	3.523 (1.418, 5.628)	0.001
CT + vs –	0.215 (−2.189, 2.619)	0.861
Sampling Time		
9–16h vs 0–8h	1.765 (−1.108, 4.638)	0.229
17–24h vs 0–8h	3.355 (0.361, 6.348)	0.028
GFAP (in log scale)	−1.483 (−2.136, −0.831)	<0.001
hsCRP (in log scale)	0.600 (−0.159, 1.359)	0.122

developing PTSD following TBI [5, 28]. However, many of these features, notably PTA, typically rely on subjective self-report. Recently, the blood-based biomarker, GFAP (a marker of astrocytic response to injury), has been identified as having clinical utility in evaluation of mTBI [16], a diagnosis which historically has also relied upon subjective symptom reporting and clinical judgement. It is therefore plausible that blood-based biomarkers could similarly be used to predict post-TBI mental health outcomes such as PTSD.

This study hypothesized that plasma levels of GFAP would correlate with PTA, a surrogate marker of injury severity [29], and with the development of PTSD. Additionally, because previous studies found a correlation between hsCRP, a non-specific peripheral marker of inflammation, and the development of PTSD [18], we hypothesized that serum hsCRP would also be associated with an increased risk for the development of PTSD, but to a lesser extent than the brain-specific marker GFAP. Consistent with our hypothesis, our data indicate that GFAP levels (which were on average substantially higher than those seen in uninjured healthy comparison subjects and in orthopedic trauma comparison subjects without TBI [30]) are associated in a dose-response fashion with duration of PTA (Fig. 1a). These data are in line with previous studies which demonstrated that both GFAP [12, 16] and duration of PTA are positively correlated with injury severity [29].

However, contrary to our hypothesis – which assumed that PTSD and TBI cause dysfunction in overlapping brain structures [31, 32] – GFAP levels were *inversely* correlated with the development of PTSD at 6 months post-injury (Table 3). Furthermore, hsCRP (Table 3), a non-specific marker of systemic inflammation, was not significantly associated with PTSD, indicating a brain-specific process. It is therefore possible that more extensive glial injury, reflected in higher levels of GFAP (and longer duration of PTA), interferes with encoding and/or consolidation of memories of the event, protecting against PTSD. In fact, previous research has indicated that shorter duration of PTA and memory of the event are predictive of PTSD [33]. Additionally, the hippocampus and its associated circuitry – structures vital to memory processes – are known to be particularly vulnerable to traumatic brain injury [34]. It will be of interest in future work to determine whether plasma GFAP levels reflect injury to specific brain structures or are a more global indicator of brain injury, and the extent to which interruption of critical neurocognitive processes impacts the development of PTSD in this context [35, 36].

GFAP levels were also significantly associated with numerous baseline factors (Table 2a). Unsurprisingly, higher levels of GFAP were seen in participants with abnormal CT scans or PTA, factors

indicative of more severe injury. Lower levels of GFAP were seen in participants who were female, had an injury associated with violence, had a previous psychiatric diagnosis, or a history of TBI. It is possible that in this cohort, individuals with these baseline demographics sustained milder brain injuries. This is similar to previous studies in which less severe injury was associated with female sex and history of TBI [19], whereas more severe TBI occurred in high-impact injury mechanisms such as motor vehicle collisions and falls.

Our multivariable model included as covariates sociodemographic and patient historical characteristics which have previously been shown to be associated with PTSD following head injury [5], indicating that plasma GFAP concentration is an independent (negative) predictor of PTSD diagnosis. Although this is a promising finding, it should be noted that although an AUC of 0.72 (seen in the multivariable model) is higher than chance, it does not meet the level required for biomarker utilization in the clinical setting (typically > 0.75) [37]. It is likely that a panel of blood biomarkers (which might well in future include genetic markers) [38] in conjunction with structural [8] or functional [39] brain imaging characteristics, possibly in conjunction with other data-driven variables derived from machine learning approaches [40], will offer better predictive validity than single biomarkers such as GFAP alone.

Strengths and limitations

Strengths of this study include its multi-center, longitudinal, prospective design, the large number of participants, use of multivariable statistical analysis, and measurement of plasma GFAP, which is already an FDA-approved biomarker to aid in the diagnosis of TBI by ruling out the need for a head CT scan. However, this study also has limitations. It was limited to adults and adolescents age 17 and older presenting to level 1 trauma centers who required a head CT scan, and had 6-month follow-up assessments. Accordingly, the findings may not be generalizable to individuals seen in community hospitals, military personnel, those without a clinical need for a CT scan, pediatric patients, those who sustained TBI but did not seek medical care, and individuals with characteristics or symptoms that prevented them from completing follow-up assessments. This study also relied on self-report of prior TBI, prior history of psychiatric illness, and PTA, which could lead to recall and reporting biases.

The gold standard for PTSD diagnosis remains a clinical interview that addresses DSM-5 criteria, but this study utilized the self-report PCL-5. Although the PCL-5 is a standardized assessment with good validity for making provisional PTSD diagnoses [21], the majority of questions do not pertain to memories of the event, and may identify individuals as potentially having PTSD when their symptoms are better attributed to mood or anxiety disorders.

CONCLUSIONS

This study showed that day-of-injury GFAP plasma level, an objective biomarker cleared by FDA to assist in the diagnosis of TBI, was correlated with duration of PTA, indicating that duration of PTA is associated with more severe pathophysiological damage. Additionally, it is the first study to show that plasma GFAP levels were inversely associated with the development of PTSD at 6 months post-injury, suggesting that increased glial activation in response to injury may be *protective* against the development of PTSD. Astrocytes have a role in both amygdala plasticity and memory consolidation [41]. While our data suggest an inverse association between glial reaction to injury and the development of PTSD, other studies show that activated astrocytes are protective against PTSD [42]. Astrocytes are known to be complex, and have heterogeneous responses dependent on injury mechanism and severity, including both adaptive and maladaptive properties [41].

Future research should be directed to investigating the role glia have in the development of PTSD in the context of TBI.

Importantly, addition of day-of-injury plasma GFAP improved the performance of previous PTSD prediction models which were based on participant demographics and injury characteristics. The current prognostic accuracy of GFAP does not meet the standards for clinical implementation to predict PTSD, but as its use as a blood-based biomarker for the extent of brain injury becomes more commonplace, clinicians should be aware that a low GFAP level does not indicate the absence of health risk to the patient. In fact, risk to mental health may be greatest in those with low ("normal") GFAP levels. Future efforts should focus on using a panel of GFAP and other blood and possibly genetic biomarkers, combined with imaging modalities, to improve prediction of the development of PTSD and related mental disorders following mTBI.

REFERENCES

- Nelson LD, Temkin NR, Dikmen S, Barber J, Giacino JT, Yuh E, et al. Recovery after mild traumatic brain injury in patients presenting to US Level I trauma centers: A transforming research and clinical knowledge in Traumatic Brain Injury (TRACK-TBI) Study. *JAMA Neurol.* 2019;76:1049–59.
- Agtarap SD, Campbell-Sills L, Jain S, Sun X, Dikmen S, Levin H, et al. Satisfaction with life after mild traumatic brain injury: A TRACK-TBI study. *J Neurotrauma.* 2021;38:546–54.
- Howlett JR, Nelson LD, Stein MB. Mental health consequences of traumatic brain injury. *Biol Psychiatry.* 2022;91:413–20.
- Albrecht JS, Abariga SA, Rao V, Wickwire EM. Incidence of new neuropsychiatric disorder diagnoses following traumatic brain injury. *J Head Trauma Rehabil.* 2020;35:E352–E360.
- Stein MB, Jain S, Giacino JT, Levin H, Dikmen S, Nelson LD, et al. Risk of post-traumatic stress disorder and major depression in civilian patients after mild traumatic brain injury: A TRACK-TBI study. *JAMA Psychiatry.* 2019;76:249–58.
- Stein MB, Kessler RC, Heeringa SG, Jain S, Campbell-Sills L, Colpe LJ, et al. Prospective longitudinal evaluation of the effect of deployment-acquired traumatic brain injury on posttraumatic stress and related disorders: Results from the army study to assess risk and resilience in servicemembers (Army STARRS). *Am J Psychiatry.* 2015;172:1101–11.
- Stein MB, McAllister TW. Exploring the convergence of posttraumatic stress disorder and mild traumatic brain injury. *Am J Psychiatry.* 2009;166:768–76.
- Stein MB, Yuh E, Jain S, Okonkwo DO, Mac Donald CL, Levin H, et al. Smaller regional brain volumes predict posttraumatic stress disorder at 3 months after mild traumatic brain injury. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2021;6:352–9.
- Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al. Traumatic brain injury: Integrated approaches to improve prevention, clinical care, and research. *Lancet Neurol.* 2017;16:987–1048.
- Shahim P, Zetterberg H. Neurochemical markers of traumatic brain injury: Relevance to acute diagnostics, disease monitoring, and neuropsychiatric outcome prediction. *Biol Psychiatry.* 2022;91:405–12.
- Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. *Nat Rev Neurol.* 2022;18:158–72.
- Papa L, Brophy GM, Welch RD, Lewis LM, Braga CF, Tan CN, et al. Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. *JAMA Neurol.* 2016;73:551–60.
- Giza CC, McCreary M, Huber D, Cameron KL, Houston MN, Jackson JC, et al. Assessment of blood biomarker profile after acute concussion during combative training among US military cadets: A prospective study from the NCAA and US department of defense CARE consortium. *JAMA Netw Open.* 2021;4:e2037731.
- McCreary M, Broglio SP, McAllister TW, Gill J, Giza CC, Huber DL, et al. Association of blood biomarkers with acute sport-related concussion in collegiate athletes: Findings from the NCAA and department of defense CARE consortium. *JAMA Netw Open.* 2020;3:e1919771.
- Yue JK, Yuh EL, Korley FK, Winkler EA, Sun X, Puffer RC, et al. Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study. *Lancet Neurol.* 2019;18:953–61.
- Bazarian JJ, Welch RD, Caudle K, Jeffrey CA, Chen JY, Chandran R, et al. Accuracy of a rapid glial fibrillary acidic protein/ubiquitin carboxyl-terminal hydrolase L1 test for the prediction of intracranial injuries on head computed tomography after mild traumatic brain injury. *Acad Emerg Med.* 2021;28:1308–17.

17. Xu LB, Yue JK, Korley F, Puccio AM, Yuh EL, Sun X, et al. High-sensitivity C-reactive protein is a prognostic biomarker of six-month disability after traumatic brain injury: Results from the TRACK-TBI Study. *J Neurotrauma*. 2021;38:918–27.
18. Michopoulos V, Rothbaum AO, Jovanovic T, Almlil LM, Bradley B, Rothbaum BO, et al. Association of CRP genetic variation and CRP level with elevated PTSD symptoms and physiological responses in a civilian population with high levels of trauma. *Am J Psychiatry*. 2015;172:353–62.
19. Yuh EL, Jain S, Sun X, Pisica D, Harris MH, Taylor SR, et al. Pathological computed tomography features associated with adverse outcomes after mild traumatic brain injury: A TRACK-TBI study with external validation in CENTER-TBI. *JAMA Neurol*. 2021;78:1137–48.
20. Haacke EM, Duhaime AC, Gean AD, Riedy G, Wintermark M, Mukherjee P, et al. Common data elements in radiologic imaging of traumatic brain injury. *J Magn Reson Imaging*. 2010;32:516–43.
21. Bovin MJ, Marx BP, Weathers FW, Gallagher MW, Rodriguez P, Schnurr PP, et al. Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (PCL-5) in veterans. *Psychol Assess*. 2016;28:1379–91.
22. Teasdale G, Jennett B. Assessment and prognosis of coma after head injury. *Acta Neurochir (Wien)*. 1976;34:45–55.
23. Manley GT, Diaz-Arrastia R, Brophy M, Engel D, Goodman C, Gwinn K, et al. Common data elements for traumatic brain injury: Recommendations from the biospecimens and biomarkers working group. *Arch Phys Med Rehabil*. 2010;91:1667–72.
24. Korley FK, Datwyler SA, Jain S, Sun X, Beligere G, Chandran R, et al. Comparison of GFAP and UCH-L1 measurements from two prototype assays: The Abbott i-STAT and ARCHITECT assays. *Neurotrauma Rep*. 2021;2:193–9.
25. van Buuren S, Groothuis-Oudshoorn K. Mice: Multivariate imputation by chained equations in R. *J Stat Softw*. 2011;45:1–67.
26. Nielson JL, Cooper SR, Seabury SA, Luciani D, Fabio A, Temkin NR, et al. Statistical guidelines for handling missing data in traumatic brain injury clinical research. *J Neurotrauma*. 2021;38:2530–7.
27. Bisson JI, Wright LA, Jones KA, Lewis C, Phelps AJ, Sijbrandij M, et al. Preventing the onset of post-traumatic stress disorder. *Clin Psychol Rev*. 2021;86:102004.
28. Van Praag DLG, Cnossen MC, Polinder S, Wilson L, Maas AIR. Post-traumatic stress disorder after civilian traumatic brain injury: A systematic review and meta-analysis of prevalence rates. *J Neurotrauma*. 2019;36:3220–32.
29. Al-Ozairi A, McCullagh S, Feinstein A. Predicting posttraumatic stress symptoms following mild, moderate, and severe traumatic brain injury: The role of post-traumatic amnesia. *J Head Trauma Rehabil*. 2015;30:283–9.
30. Okonkwo DO, Puffer RC, Puccio AM, Yuh EL, Yue JK, Diaz-Arrastia R, et al. Point-of-care platform blood biomarker testing of glial fibrillary acidic protein versus s100 calcium-binding protein B for prediction of traumatic brain injuries: A transforming research and clinical knowledge in traumatic brain injury study. *J Neurotrauma*. 2020;37:2460–7.
31. Howlett JR, Stein MB. Prevention of trauma and stressor-related disorders: A review. *Neuropsychopharmacology*. 2016;41:357–69.
32. Kaplan GB, Leite-Morris KA, Wang L, Rumbika KK, Heinrichs SC, Zeng X, et al. Pathophysiological bases of comorbidity: Traumatic brain injury and post-traumatic stress disorder. *J Neurotrauma*. 2018;35:210–25.
33. Cnossen MC, Scholten AC, Lingsma HF, Synnot A, Haagsma J, Steyerberg PEW, et al. Predictors of major depression and posttraumatic stress disorder following traumatic brain injury: A systematic review and meta-analysis. *J Neuropsychiatry Clin Neurosci*. 2017;29:206–24.
34. Bigler ED. Volumetric MRI Findings in Mild Traumatic Brain Injury (mTBI) and Neuropsychological Outcome. *Neuropsychol Rev*. 2021. <https://doi.org/10.1007/s11065-020-09474-0>.
35. Jacob SN, Dodge CP, Vasterling JJ. Posttraumatic stress disorder and neurocognition: A bidirectional relationship? *Clin Psychol Rev*. 2019;72:101747.
36. Van Praag DLG, Van Den Eede F, Wouters K, Wilson L, Maas AIR. The Center-TBI Investigators and Participants. The impact of neurocognitive functioning on the course of posttraumatic stress symptoms following civilian traumatic brain injury. *J Clin Med*. 2021;10:5109.
37. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. *JAMA* 2017;318:1377–84.
38. Stein MB, Levey DF, Cheng Z, Wendt FR, Harrington K, Pathak GA, et al. Genome-wide association analyses of post-traumatic stress disorder and its symptom subdomains in the Million Veteran Program. *Nat Genet*. 2021;53:174–84.
39. Neria Y. Functional Neuroimaging in PTSD: From discovery of underlying mechanisms to addressing diagnostic heterogeneity. *Am J Psychiatry*. 2021;178:128–35.
40. Schultebrucks K, Shalev AY, Michopoulos V, Grudzen CR, Shin SM, Stevens JS, et al. A validated predictive algorithm of post-traumatic stress course following emergency department admission after a traumatic stressor. *Nat Med*. 2020;26:1084–8.
41. Zhou Y, Shao A, Yao Y, Tu S, Deng Y, Zhang J. Dual roles of astrocytes in plasticity and reconstruction after traumatic brain injury. *Cell Commun Signal*. 2020;18:62.
42. Jones ME, Paniccia JE, Lebonville CL, Reissner KJ, Lysle DT. Chemogenetic manipulation of dorsal hippocampal astrocytes protects against the development of stress-enhanced fear learning. *Neuroscience* 2018;388:45–56.

AUTHOR CONTRIBUTIONS

The authors noted here have made substantial contributions to the conception or design of the work (LND, FKK, PM, DOO, JTG, CSR, MAM, KKWW, NT, CLM, RD-A, GTM, MBS); or the acquisition (LND, FKK, DOO, MJV, CSR, MAM, SRT, RD-A, GTM), analysis (SJ, XS), or interpretation of data (JRK, SJ, LND, FKK, XS, DOO, JTG, MAM, NT, ARF, AJM, RD-A, GTM, MBS) for the work; and Drafting the work or revising it critically for important intellectual content (all authors); and final approval of the version to be published (all authors); and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved (MBS, GTM).

FUNDING

This research was supported by the National Institutes of Health (grant U01NS086090) and US Department of Defense (grant W81XWH-14-2-0176). Abbott Laboratories provided funding for add-in TRACK-TBI clinical studies. One Mind provided funding for TRACK-TBI patients' stipends and support to clinical sites. Dr. Manley discloses grants from the United States Department of Defense – TBI Endpoints Development Initiative (Grant #W81XWH-14-2-0176), TRACK-TBI Precision Medicine (Grant # W81XWH-18-2-0042), and TRACK-TBI NETWORK (Grant # W81XWH-15-9-0001); NIH-NINDS – TRACK-TBI (Grant #U01NS086090); and the National Football League (NFL) Scientific Advisory Board – TRACK-TBI LONGITUDINAL. United States Department of Energy supports Dr. Manley for a precision medicine collaboration. He has received an unrestricted gift from the NFL to the UCSF Foundation to support research efforts of the TRACK-TBI NETWORK. Dr. Manley has also received funding from NeuroTrauma Sciences LLC to support TRACK-TBI data curation efforts. Amy Markowitz receives funding from the Department of Defense TBI Endpoints Development Initiative (Grant #W81XWH-14-2-0176) and TRACK-TBI NETWORK (Grant # W81XWH-15-9-0001). Ms. Markowitz also receives salary support from the United States Department of Energy precision medicine collaboration. Dr. Yuh had a patent for USPTO No. 62/269,778 pending. Dr. Stein received personal fees from Acadia, Aptinyx, Bionomics, Boehringer-Ingelheim, EmpowerPharm, Engrail Therapeutics, Genentech/Roche, GW Pharma, Janssen, and Jazz Pharmaceuticals; as well as stock options from Oxeia Biopharmaceuticals and EpiVario outside the submitted work. Dr. Diaz-Arrastia received personal fees and research funding from Neural Analytics Inc and travel reimbursement from Brain Box Solutions Inc outside the submitted work. Dr. Mukherjee received grants from GE Healthcare and nonfinancial support from GE-NFL Head Health Initiative outside the submitted work; in addition, Dr. Mukherjee had a patent for USPTO No. 62/269,778 pending. Dr. Zafonte received royalties from Oakstone for an educational CD (Physical Medicine and Rehabilitation: a Comprehensive Review) and Demos publishing for serving as coeditor of *Brain Injury Medicine*. Dr. Zafonte serves or served on the scientific advisory boards of Myomo, and One care.ai. He also evaluates patients in the MGH Brain and Body-TRUST Program, which is funded by the National Football League Players Association. Dr. Zafonte served on the Mackey White Committee. The other authors have no disclosures.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41386-022-01359-5>.

Correspondence and requests for materials should be addressed to Murray B. Stein.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the

article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022, corrected publication 2022

TRACK-TBI INVESTIGATORS

Neeraj Badjatia¹⁸, Ann-Christine Duhaime¹⁹, V. Ramana Feeser²⁰, C. Dirk Keene²¹, Christopher Madden²², Randall Merchant²⁰, Ava Puccio⁷, David Schnyer²³, Sabrina R. Taylor²⁴, Alex Valadka²⁰, John K. Yue¹⁰, Esther L. Yuh⁵ and Ross Zafonte⁸

¹⁸University of Maryland, College Park, USA. ¹⁹MassGeneral Hospital for Children, Boston, USA. ²⁰Virginia Commonwealth University, Richmond, USA. ²¹University of Washington, Seattle, USA. ²²UT Southwestern, Dallas, USA. ²³UT Austin, Austin, USA. ²⁴University of California, San Francisco, USA.